The second affiliated hospital of Nanjing Medical University
Nanjing, Jiangsu, 210011, China
Location status: Recruiting
NCT Number: NCT06106698
This is a real-world study to explore the safety and the efficacy of washed microbiota transplantation (WMT) for patients with Clostridioides Difficile Infection (CDI).
Interested in participating?
Request Info3 year–100 year
All sexes
Observational
Nanjing, Jiangsu, 210011, China
Location status: Recruiting
At least 12 subjects who meet all the inclusion criteria but do not meet any exclusion criteria will be enrolled in this study. Data of demographic characteristics, intestinal symptoms, medicine treatment usage and clinical outcomes will be collected. After treatment, they will enter the follow-up period (at least for 4-week post-WMT)for safety and efficacy evaluation. Subjects with no response and recurrence will receive salvage therapy, and the extended follow-up period will be performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects must meet all of the following inclusion criteria to enter the study:
Exclusion criteria
Subjects meeting any of the following exclusion criteria must be excluded from the study:
Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive one dose of WMT for CDI. During follow-up, those who have non-response or CDI recurrence within 4-week post-WMT will receive rescue WMT.
Time frame: Four-week post-WMT
The severity of AE was graded as mild (grade 1), moderate (grade 2), severe/disabling (grade 3), life threatening (grade 4), and death (grade 5). All AE were divided in definitely, probably and possibly related to treatment. The treatment-related AE we focused on included microbiota-related AEs (e.g., infection, diarrhea, abdominal pain, etc.) and route of delivery related AEs (e.g., nausea, vomiting, etc.).
Time frame: Four-week post-WMT,eight-week post-WMT
The complete response of CDI-related diarrhea was defined as there was no diarrhea (1-2 times/day) for at least two consecutive days (normal stool characteristics (Bristol score ≤5) after treatment.
Time frame: Four-week post-WMT,eight-week post-WMT
Recurrence was defined as the CDI-related diarrhea reappeared, and the Clostridium difficile toxin test was positive after achieving complete response.
Time frame: One-week post-WMT,Two-week post-WMT
Disease progression refers to the worsening of symptoms associated with CDI, including increased diarrhea, toxic megacolon, organ failure, the need for emergency colectomy, and even death.
Time frame: Eight-week post-WMT,six-month-post-WMT
The severity of AE was graded as mild (grade 1), moderate (grade 2), severe/disabling (grade 3), life threatening (grade 4), and death (grade 5). All AE were divided in definitely, probably and possibly related to treatment. The treatment-related AE we focused on included microbiota-related AEs (e.g., infection, diarrhea, abdominal pain, etc.) and route of delivery related AEs (e.g., nausea, vomiting, etc.).
Contact information is provided by the study sponsor or research team.
Bota Cui
CONTACT
Faming Zhang, PhD
CONTACT
The Second Hospital of Nanjing Medical University
Other
Washed Microbiota Transplantation for Clostridioides Difficile Infection: a Real World Research
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06237452
Bacterial Infections, Bacterial Infections and Mycoses
Huntsville, Alabama, United States
View Trial DetailsNCT07285213
Bacterial Infections, Bacterial Infections and Mycoses
Phoenix, Arizona, United States
View Trial DetailsNCT05266807
Bacterial Infections, Bacterial Infections and Mycoses
Basel, Switzerland
View Trial DetailsNCT07613645
Bacterial Infections, Bacterial Infections and Mycoses
Ann Arbor, Michigan, United States
View Trial Details